Primary localised renal cell cancer of clear cell subtype Cancer
Conditions
Interventions
The researchers will invite adults from participating hospitals in England and Scotland who have had surgery for kidney cancer to take part in the study. Potential participants will be invited to take
Sponsors
Cambridge University Hospitals NHS Foundation Trust
University of Cambridge
Eligibility
Sex/Gender
All
Age
18 Years to 120 Years
Inclusion criteria
Inclusion criteria: 1. Patients treated with surgery for primary localised kidney cancer awaiting their first follow-up appointment after discharge 2. RCC is of clear cell subtype 3. Aged 18 years or over 4. Able to read and write in English 5. Able to understand and sign the written Informed Consent Form
Exclusion criteria
Exclusion criteria: 1. Patients known to have any condition, which in the opinion of the local principal investigator makes the subject unsuitable for study participation 2. Patients with a known familial syndrome 3. Patients with a second primary kidney cancer
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary aim of this study is to assess the feasibility and acceptability of incorporating the PREDICT Kidney online tool into the first post-surgery follow-up appointments for patients with localised renal cell carcinoma and to evaluate participant recruitment, completeness of data collection and estimates of patient-level outcomes to inform the design of a future trial. As such, the primary outcomes are: 1. Uptake into the study measured by the proportion of eligible patients invited to participate who consent to take part measured at the completion of recruitment 2. Completeness of data collection measured by the proportion of patients who consent to participate in the trial who complete the questionnaires measured at the completion of recruitment 3. The time needed to use the tool and any change in the overall length of consultation measured by the delivery time of the PREDICT Kidney tool during consultation appointments (intervention group only) and the length of consultation appointments (both groups) 4. The acceptability of integrating the tool into clinical care to patients and clinicians assessed in interviews 2-6 weeks post consultation 5. The adherence to the study “best-practice” guide by clinicians and variability between clinicians and sites in the use of the tool measured by clinician adherence to the “best practice” checklist within the consultation 6. Estimates of patient-level clinical outcomes to inform the choice of outcomes for a subsequent trial, including: 6.1. Subjective comprehension of risk of recurrence and follow-up measured using questionnaire items immediately post-consultation 6.2. Objective comprehension of risk of recurrence measured using questionnaire items immediately post consultation and at 3 months post-consultation 6.3. Perceived risk of cancer recurrence measured using questionnaire items immediately post consultation and at 3 months post-consultation 6.4. Risk conviction measured immediately using questionnaire items post | — |
Secondary
| Measure | Time frame |
|---|---|
| There are no secondary outcome measures | — |
Countries
England, Scotland, United Kingdom
Contacts
Public ContactJessica Kitt
Outcome results
None listed